Geron Stock (NASDAQ:GERN)
Previous Close
$4.25
52W Range
$1.64 - $5.34
50D Avg
$4.31
200D Avg
$3.80
Market Cap
$2.49B
Avg Vol (3M)
$8.10M
Beta
0.52
Div Yield
-
GERN Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
TGTX | TG Therapeutics, Inc. |
PTCT | PTC Therapeutics, Inc. |
CWBR | CohBar, Inc. |
PDSB | PDS Biotechnology Corporation |
SRPT | Sarepta Therapeutics, Inc. |
AVRO | AVROBIO, Inc. |
VKTX | Viking Therapeutics, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
OCEA | Ocean Biomedical, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |
ZURA | Zura Bio Limited |
ELEV | Elevation Oncology, Inc. |
ENVB | Enveric Biosciences, Inc. |